logo
High hopes as Germany's Merz meets US President Trump – DW – 06/04/2025

High hopes as Germany's Merz meets US President Trump – DW – 06/04/2025

DW3 days ago

Will German Chancellor Friedrich Merz convince US President Donald Trump to be a reliable partner to Europe? Expectations are high for Merz's first visit to Washington.
Friedrich Merz and Donald Trump have already exchanged private cell phone numbers and they are on a first-name basis, but aside from a brief encounter in New York years ago, this Thursday will be the first time that the two leaders meet.
The new German Chancellor Friedrich Merz of the conservative Christian Democratic Union (CDU) is on his inaugural visit to Washington. Merz, like former chancellor Angela Merkel, the British Queen Elizabeth and French President Charles de Gaulle before him, has been invited to stay at the Blair House, directly adjacent to the White House.
It was only a few weeks ago that Merz expressed strong disapproval of events in the Oval Office in March, when the US president publicly ridiculed Ukrainian President Volodymyr Zelenskyy and blamed him for Russia's war against his country. Merz also took issue with Vice President JD Vance and other Trump associates for expressing support for Germany's far-right Alternative for Germany party (AfD).
How Merz aims to regain Germany's standing on foreign issues
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Committed to trans Atlantic cooperation
Recently, the German chancellor told public broadcaster WDR how his first telephone conversation with Donald Trump went: "It's always important not to talk for too long, but to keep it short and also let him talk."
According to Merz, every second or third word the president said was "great."
"You have to adapt your approach and work with him. At the same time, we mustn't make ourselves smaller than we are," said Merz. "We are not supplicants."
Carlo Masala, professor of international politics at the Bundeswehr University in Munich, also thinks Merz needs to be confident going into his meeting with Trump.
Masala told public broadcaster NDR: "He needs to be assertive, but at the same time make Trump feel respected as a great statesman with a strong vision. I believe that flattery combined with European self-confidence is the best strategy, although there is no guarantee that it will ultimately be successful."
The talks in Washington are likely to focus on three major issues: the war in Ukraine, the tariff disputes, and the question of Europe's contribution to its own security.
On security issues, Merz can now point to some achievements. Trump has repeatedly complained about the low defense spending of some European NATO partners, including Germany, and threatened to withdraw US protection. Now Merz can say that Germany is planning a massive military build-up: Five percent of Germany's GDP will be allocated to defense in the future, with 3.5% going directly to the military and 1.5% to defense-related infrastructure.
German FM: Germany to ramp up defense spending
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Tariffs and defense
Germany is also seeking to assume a greater leadership role in Europe. The joint visit made to Kyiv by the heads of state of Germany, France, Great Britain and Poland to show their support, which was initiated by Merz, demonstrated Europe's willingness to meet the American demand that it takes responsibility for its own security affairs. In return, Merz and other European leaders hope to work with the US to increase pressure on Russian President Vladimir Putin.
On the issue of tariffs, Merz has no authority to negotiate because trade policy is a EU matter. But as an export nation, Germany is getting hit hard by trade barriers. On the day Merz departed, US import tariffs on European steel and aluminum doubled to 50%. The chancellor is likely to urge both sides to avoid an escalating trade conflict in which everyone loses.
Friedrich Merz is very much a trans Atlanticist. He is likely to try to convince Donald Trump that it is also in his own interest for the US to remain committed to Europe.
But political scientist Carlo Masala is pessimistic: "I believe that any long-term strategy that can work must assume that the United States will pull out of the negotiations between Russia and Ukraine."
Europeans will have to be prepared for the US, as Ukraine's most important supporter, to withdraw, Masala said.
"And to move quickly when it comes to the question of European defense capabilities and sovereignty," he said. "That is the long-term strategy."
Trump threatens 50% tariffs on EU imports
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Will Trump visit his ancestral home in Germany?
With the new federal government made up of the conservative CDU/CSU and the Social Democrats (SPD), a new style has also emerged in foreign policy. Former Green Party Foreign Minister Annalena Baerbock was sometimes criticized for being moralizing and patronizing.
The new government now wants to focus more on common interests and finding compromises, even with difficult partners, such as the Trump administration.
The conflicts between Germany and the US are numerous, and Friedrich Merz and Donald Trump are very different characters. But the German chancellor is determined to engage openly with the US president. Echoing a move by former Chancellor Angela Merkel, Friedrich Merz has invited the US president to visit the homeland of his ancestors. Trump's grandfather, Friedrich Trump, grew up in the winegrowing village of Kallstadt in the Palatinate region of Germany before emigrating to the US.
It is not yet known whether Trump will accept the invitation this time.
This article was originally written in German.
While you're here: Every Tuesday, DW editors round up what is happening in German politics and society. You can sign up here for the weekly email newsletter, Berlin Briefing.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed
The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed

Int'l Business Times

time5 hours ago

  • Int'l Business Times

The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed

In recent years, Chinese investment in U.S. and global biotech and medtech has increased significantly. These partnerships can serve as strategic footholds, raising complex questions around security, sovereignty, and long-term strategy. Consider Grand Pharmaceutical Group, also known as Yuanda Pharmaceutical and Grand Pharma, which jointly acquired Australian firm Sirtex Medical, forged a nuclear medicine collaboration with Sirtex Medical U.S., and took an 87.5% stake in BlackSwan Vascular, a U.S.-based developer of vascular embolization technologies. On the surface, Grand Pharma looks like a modern success story. Hu Kaijun, a Chinese billionaire, holds a majority stake in Grand Pharma, positioning him as a key figure in the company's global expansion in the life sciences sector. Under his leadership, Grand Pharma has diversified its portfolio through strategic acquisitions and collaborations, enhancing its presence in the international market. But for U.S. life sciences stakeholders, don't be misled: Grand Pharma's rise isn't just a story of business savvy—it's a case study in how state-backed capital can reshape a company. And for founders, it's a reminder that funding sources can carry strategic baggage. Grand Pharma's aggressive expansion may reflect a broader trend of Chinese firms investing in advanced markets to access Western R&D and expand China's presence more deeply in the future of global biomedical innovation—a trend that raises serious concerns for U.S. interests. From State-Owned Roots to Global Reach Through strategic investments and collaborations, Kaijun and Grand Pharma continue to expand their footprint, resulting in the transfer of cutting-edge medical technologies from European and U.S. startups to China. Behind Grand Pharma's rapid rise lies a more complex history—one that raises questions about influence, oversight, and strategic intent. Before Grand Pharma was a global healthcare investor, it was a modest state-owned enterprise (SOE) in China under the purview of the Poverty Alleviation Office. Its mission: deliver pharmaceutical products as a public good, not a profit engine. But in the late 1990s and early 2000s, that began to change. A 2013 investigation by China Finance (CNFINA) suggested that Kaijun played a significant role in transforming the SOE into China Grand Enterprises through a series of complex transactions that have raised questions about corporate governance and asset valuation. One notable transaction highlighted in the CNFINA report involves Yanhuang Real Estate, a private firm not previously affiliated with the company. The firm purchased 50% of China Grand Enterprises from two state-owned shareholders for 50 million yuan. This transaction was justified using China Grand's initial registered capital of 100 million yuan. However, estimates based on the net assets held by China Grand at the time suggested that those shares were worth at least 145 million yuan, indicating a potential undervaluation of approximately 95 million yuan. The CNFINA report details that two additional state-owned entities transferred their 50% stake to four private investment firms, including Beijing Taihua Yongchang Investment and Beijing Dongfang Weichuang, for similarly underpriced amounts based on outdated registered capital. CNFINA's analysis estimated the value of these two transfers combined to have resulted in a total undervaluation of over 218 million yuan. This suspicious restructuring is significant because it offers a window into how power and capital were initially consolidated, and under what terms. Transactions that undervalue assets and move them out of public hands raise fundamental concerns about transparency, governance, and intent. When such origins lead to foreign acquisitions in sensitive sectors like biotechnology, it becomes even more important to scrutinize the business culture and strategic motivations behind the capital. In short, where the wealth comes from and how it was made offer important clues into how business leaders operate their companies. The Fine Print of Chinese Capital For U.S. life sciences startups, the lesson is clear: capital isn't neutral. The wrong investor can bring not just regulatory headaches but long-term strategic consequences. A growing list of cases tells a cautionary tale. Sirtex Medical When Grand Pharma and CDH Investments outbid Varian by a reported 20% to acquire Sirtex Medical, observers raised questions about the surprisingly high acquisition price. Through its subsidiary Chengdu Shetai, Grand Pharma has since leveraged Sirtex's platform to accelerate its development of nuclear medicine therapies. In cases of majority foreign ownership, especially by companies with potential state affiliations, it invites questions about data governance, manufacturing control, and regulatory visibility. More Lessons from BGI, WuXi, and Others Grand Pharma isn't the only example. Chinese biotech giants like BGI Group and WuXi AppTec have drawn attention in recent years over concerns related to data use, military ties, and participation in U.S. research networks. These cases underscore a growing sensitivity: capital flows from companies with strategic state interests may pose challenges in sensitive sectors like life sciences. A recent TechTimes article breaks down the core risks facing U.S. life sciences companies in the face of growing Chinese investment, from academic partnerships enabling access to sensitive research to financial ties that quietly shift control, and nefarious enterprises evading regulatory scrutiny. The piece argues that while the proposed BIOSECURE Act legislation is a step in the right direction, it lacks the enforcement teeth needed to truly safeguard American innovation in the life sciences sector. Ultimately, U.S. biotech and medtech startups must take proactive responsibility for who they partner with because policy alone won't protect what's not carefully guarded from the start. A Critical Reminder for Founders and CEOs: Capital Comes with Consequences U.S. life sciences startups face an increasingly complex landscape. Fast, global capital may seem like an obvious win, but it can introduce long-term complications. These include heightened regulatory oversight, potential deal restrictions, and reputational considerations. As geopolitical tensions evolve, particularly between the U.S. and China, biotech and medtech are emerging as points of scrutiny. In an interview on Chinese firms facing U.S. Commerce Department action related to AI, Gordon Chang, a senior fellow at the Gatestone Institute and a specialist on U.S.-China relations, stated, "all Chinese companies are a threat." While his comment was made in the context of national security and advanced technologies, it reflects a broader concern among some policymakers and analysts: that Chinese firms, regardless of sector, may operate with implicit state alignment, especially when national strategic interests are involved. For biotech and medtech companies, choosing the right partner now depends as much on who they are as what they offer. For the foreseeable future, U.S. startups should approach foreign investment, especially from state-influenced entities, with caution and care. This isn't just about one company or one country. It's about building resilient innovation ecosystems that can withstand geopolitical shifts while preserving trust, competitiveness, and scientific integrity.

Musk Fires Back With Slur After Steve Bannon Called for Trump to Seize SpaceX, Deport the CEO
Musk Fires Back With Slur After Steve Bannon Called for Trump to Seize SpaceX, Deport the CEO

Int'l Business Times

time10 hours ago

  • Int'l Business Times

Musk Fires Back With Slur After Steve Bannon Called for Trump to Seize SpaceX, Deport the CEO

Elon Musk hurled slurs after former Trump strategist Steve Bannon called for the president to seize SpaceX and deport Musk following his public tirade against President Donald Trump and his support for Republicans' "one big, beautiful bill." Bannon railed against Musk and his work with the Department of Government Efficiency during the Thursday episode of his "War Room" podcast, in which he claimed that Trump was upset that Musk "didn't find any fraud." STEVE BANNON: "President Trump, TONIGHT, should sign an executive order calling up the Defense Production Act, and seize SpaceX TONIGHT, before midnight." — Eric Daugherty (@EricLDaugh) June 5, 2025 "When he threatens to take one of the big programs out of SpaceX, President Trump tonight should sign an executive order calling for the Defense Production Act to be called and seize SpaceX tonight before midnight," Bannon declared. Clips of this part of the podcast were then shared to X, Musk's social media platform, where Musk had some choice words to reveal his thoughts toward Bannon's ideas. Bannon is peak retard — Elon Musk (@elonmusk) June 6, 2025 "Bannon is peak r*****," the Tesla CEO commented after the video was reposted to by the popular X account "R***** Finder." Musk then doubled down on the sentiment hours later in another comment after another user shared the same clip: "Bannon is a communist r*****." Bannon is a communist retard — Elon Musk (@elonmusk) June 6, 2025 Earlier in the day, Bannon had called for Musk to be deported, telling the New York Times , "They should initiate a formal investigation of his immigration status because I am of the strong belief that he is an illegal alien, and he should be deported from the country immediately." Bannon's support for Trump continued after Musk posted a series of scathing tweets directed at the president over Republicans' "big, beautiful bill" which Trump has expressed support for. Although Musk served as a close ally of Trump for the past several months, he explained that he believes the spending bill would undermine the work of DOGE, as current estimates suggest the bill will raise the national deficit by several trillion dollars. While Musk's tweets initially just railed against the bill and dug up tweets from Trump's past where he expressed opposition to raising the national deficit, the tirade later became more accusatory, claiming that the files on Jeffrey Epstein have not been released yet because Trump's name is in them. Trump and the White House have not addressed this accusation, though he told ABC News Friday that he is "not particularly" interested in talking to Musk anytime soon. Originally published on Latin Times Elon musk Donald trump Spacex

Musk's Rage 'Helps Bolster' GOP Senator's Efforts Against Trump's 'Big, Beautiful Bill,' Lawmaker Says
Musk's Rage 'Helps Bolster' GOP Senator's Efforts Against Trump's 'Big, Beautiful Bill,' Lawmaker Says

Int'l Business Times

time12 hours ago

  • Int'l Business Times

Musk's Rage 'Helps Bolster' GOP Senator's Efforts Against Trump's 'Big, Beautiful Bill,' Lawmaker Says

Sen. Ron Johnson said Elon Musk's explosive criticism of Donald Trump's sweeping tax-and-spending plan helps reinforce Republican opposition to the bill, which some in the GOP warn will worsen the federal deficit. The latest divide within the party comes as lawmakers debate Trump's so-called "One Big Beautiful Bill," a legislative package that his allies say fulfills campaign promises but that fiscal conservatives like Johnson argue is too costly. Musk's public meltdown over the bill, paired with his threats to oust supporters and revelations that he donated over $250 million to Trump's campaign, has further complicated the politics surrounding the measure, the Milwaukee Journal Sentinel reported. In a series of social media posts this week, Musk claimed Trump wouldn't have been reelected without him, accused the former president of ties to the Jeffrey Epstein investigation, and called for his impeachment. Trump fired back by threatening Musk's federal contracts and accusing him of trying to sabotage the legislation to protect electric vehicle tax breaks for Tesla. While Johnson welcomed Musk's support in questioning the bill's fiscal impact, other Republicans brushed off the feud. Rep. Derrick Van Orden called the dustup a "tempest in a teapot" and reiterated his loyalty to Trump. "I think it has an impact," Johnson said. "I think it helps bolster, certainly, my case that we have to address this." Rep. Tom Tiffany said Musk's input came too late to make a difference. Still, some lawmakers acknowledged that the billionaire's comments aren't helping the GOP unify behind the bill. Rep. Scott Fitzgerald said Musk's attacks weren't "helpful," and Rep. Troy Nehls accused Musk of having "lost [his] damn mind." Despite the fallout, Van Orden said the legislation will move forward and insisted Trump is still leading the GOP. Originally published on Latin Times

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store